Digital Data Collection to Measure the Impact of Myasthenia Gravis on Patients' Quality of Life in the Real World: Report at Baseline
Author(s)
Dewilde S1, Kousoulakou H2, Janssen M3, Claeys K4, Friconneau M5, Jacob S6, Meisel A7, Day L8, Quinn C8, Larkin M9, Leighton T10, Phillips G11, Paci S10
1SHE, Brussels, VBR, Belgium, 2Freelance consultant, Athens, Greece, 3Erasmus MC, Rotterdam, ZT, Netherlands, 4University Hospitals Leuven, Leuven, Belgium, 5AFM Téléthon, Paris, France, 6University Hospitals Birmingham, Birmingham, UK, 7Center for Stroke Research Berlin, Berlin, Germany, 8Vitaccess Ltd, Oxford, UK, 9Vitaccess, London, LON, UK, 10Argenx BVBA, Ghent, Belgium, 11argenx Inc, Boston, NY, USA
OBJECTIVES Myasthenia gravis (MG) is a neuromuscular disorder causing weakness in arms, legs, double vision, and problems with speech, eating and breathing. This study sets out to report how MG affects patients’ health-related quality-of-life (HRQoL) in a real-world setting. METHODS A digital, prospective, observational, longitudinal study collected data using a smartphone/tablet application among 840 MG patients in Belgium, Canada, Germany, Italy, Japan, Spain, UK and USA. At baseline, patients filled in demographic, disease-related (MG Foundation of America score: MGFA), clinical (MG-Activities of Daily Living: MG-ADL, MG-Quality of life: MG-QoL, Hospital Anxiety and Depression: HADS), caregiver and HRQoL data (EQ-5D-5L). RESULTS 617 MG patients (70% female, mean age 47 (IQR 36-58)) completed the EQ-5D-5L at baseline. The mean utility was 0.688 (IQR 0.599-0.837)), compared to 0.855 in the general population of the same age and gender. Age and gender had no noteworthy impact on utilities. In univariable analyses, utility was significantly associated with disease severity: for MGFA classes 1-5 utilities were respectively: 0.811, 0.766, 0.648, 0.527, 0.360 (p=<.0001). Highly significant negative associations were found with MG-ADL and MG-QoL total scores: a 1-point worsening in these scores corresponded with a utility decline of 0.0375 and 0.0207, respectively (both p=<.0001). The impact of mild, moderate and severe depression was associated with dis-utilities of -0.121, -0.230 and -0.408 (p=<.0001), and for mild, moderate and severe anxiety dis-utilities were -0.078, -0.147 and -0.252 (p=<.0001). Needing help from a caregiver generated a disutility of -0.236, and this was significantly associated with the number of hours of help received. A significant worsening in utility values was also found for patients with additional co-morbidities (-0.105, p=<0.0001). CONCLUSIONS MG patients have impaired HRQoL. The severity of the disease, the activities of daily living, their physical and mental health, and the necessity for a caregiver all significantly affect patients’ HRQoL.
Conference/Value in Health Info
2021-11, ISPOR Europe 2021, Copenhagen, Denmark
Value in Health, Volume 24, Issue 12, S2 (December 2021)
Code
POSC375
Topic
Medical Technologies, Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Digital Health, Health State Utilities, Patient-reported Outcomes & Quality of Life Outcomes, PRO & Related Methods
Disease
Neurological Disorders
Explore Related HEOR by Topic